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pstream/Downstream
lycoprotein IIb/IIIa
n Non–ST-Segment
levation Myocardial Infarction*
ri Ben-Yehuda, MD, FACC
an Diego, California
latelets play a critical role in the atherothrombosis of
yocardial infarction (MI). Whether the initial insult is
laque rupture or plaque erosion (1), platelet adhesion with
ubsequent activation and aggregation is regarded as the
ext event leading to thrombus formation. If the resultant
hrombus is totally occlusive ST-segment elevation myocar-
ial infarction (NSTEMI) is likely to occur, whereas non-
cclusive thrombus is likely to lead to NSTEMI/unstable
ngina (UA). The NSTEMI compromise the vast majority
f MI cases, accounting for approximately 1.2 million
nnual discharges in the U.S. (2). Although the early
rognosis is better for NSTEMI, long-term outcomes are
imilar for both, mainly because of the risk of re-infarction
n the patients with NSTEMI.
See pages 522 and 529
Since the identification of the role of platelets in MI,
nti-platelet therapy has continued to evolve, with both
ncreasing treatment options and increasing under-
tanding of the various complex pathways involved.
latelets may be activated by a myriad of agonists
thrombin, epinephrine, collagen, thromboxane, seroto-
in, adenosine-5=-diphosphate, von Willebrand factor,
nd so on) through various receptors involving complex sig-
aling pathways (3). Platelet aggregation, the occurrence of
ross-linking between platelets to form a “white thrombus”,
equires the activation of a common final pathway, the
lycoprotein (GP) IIb/IIIa receptor-mediated linking of
ne platelet to another by binding to fibrinogen and in
igh-shear-stress conditions to von Willebrand factor.
iven that platelets may be activated by multiple pathways
ut aggregate through a single pathway, the GP IIb/IIIa
eceptor emerged, based on the pioneering work of Coller et
l. (4), as an attractive target in the treatment of arterial
hrombosis. Glycoprotein IIb/IIIa inhibition has been
hown by our group to improve myocardial perfusion in an
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, University of California, San Diego. Dr.
en-Yehuda has received honoraria and research grants from Merck, Guilfordm
harmaceuticals, and Millennium Pharmaceuticals, the previous makers/marketers of
irofiban and eptifibatide.nimal model of ischemia/reperfusion (5), providing mech-
nistic data for the beneficial effects during percutaneous
oronary intervention (PCI) for MI.
Early on, several GP IIb/IIIa inhibitors were developed,
otably the monoclonal antibody abciximab and the small
olecules tirofiban and eptifibatide. For all three com-
ounds randomized clinical trial evidence has shown reduc-
ion in re-infarction rates, and rehospitalization for acute
oronary syndrome [CAPTURE (6) with abciximab,
RISM-PLUS (7) with tirofiban, and PURSUIT (8) with
ptifibatide] though mortality reductions (particularly at six
onths or longer) have been less conclusively shown (9).
oreover, the TACTICS-TIMI 18 (10) trial showed that
n the presence of anti-IIb/IIIa therapy an invasive approach
s preferable in NSTEMI patients and UA patients with
T-segment depressions. Despite class I indication per the
merican College of Cardiology/American Heart Associa-
ion guidelines (11) for patients with NSTEMI/UA likely
o undergo PCI, the use of GP IIb/IIIa in NSTEMI
atients is only 20% (12), and only 12.8% in elderly patients
13). Multiple factors account for this low use: concern over
leeding risk, uncertainty over the best time to initiate
herapy (upstream or in the catheterization laboratory), the
mergence of the thienopyridines as alternative anti-platelet
gents, and the development of direct thrombin inhibitors
uch as bivalirudin.
In this issue of the Journal, two reports on the use of GP
Ib/IIIa in the setting of NSTEMI/UA provide useful
nformation that may help guide clinicians in the use of
hese agents. The first, the relatively small but well-designed
VEREST (14) trial, randomized patients to upstream versus
n-catheterization-laboratory initiation of GP IIb/IIIa an-
agonists. The upstream arm received the standard dose of
irofiban, as used in the PRISM-PLUS and TACTICS
rials. The in-catheterization-laboratory arm received either
bciximab or a new higher dose of tirofiban, which has been
dentified as yielding greater platelet inhibition than the
n-catheterization-laboratory dose used in the TARGET
rial (15). The results, although preliminary and needing
erification in a larger trial, are intriguing. The patients in
he upstream arm had better myocardial perfusion both on
rrival in the catheterization laboratory and at the end of
heir procedure, as compared with the higher-dose tirofiban
nd abciximab patients, who had therapy initiated in the
atheterization laboratory. Why might this be so? Why
ould a lower dose of tirofiban outperform a higher dose
nitiated during the time of PCI? Although some events do
ccur upstream while awaiting catheterization, the overall
vent rate during that waiting period in patients receiving
spirin and anticoagulation with heparin is low, so that the
enefit of GP IIb/IIIa blockers during the upstream time
eriod in absolute terms is small. Rather, the benefit is more
ikely to occur during and immediately after PCI. Indeed, a
revious report in this Journal provided evidence on a
echanistic level that GP IIb/IIIa inhibitors may not only
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February 7, 2006:538–40 Editorial Commentrevent thrombus formation (and propagation) but may also
ead to dissolution of platelet aggregates already formed in
igh-shear situations (16), with up to 75% thrombus disso-
ution. Thus the upstream use of the agent may lead to a
ower thrombus load at the start of the procedure, hence less
otential for distal embolization during the procedure (17).
The second report (18) in this issue of the Journal
ddresses the issue of upstream versus in-catheterization-
aboratory initiation of GP IIb/IIIa from the cost-
ffectiveness viewpoint. Using decision analysis methodol-
gy, the investigators compared the use of upstream small
olecules (tirofiban and eptifibatide) in all comers with
STEMI/UA (referred to as acute coronary syndrome pa-
ients in the study) versus selective in-catheterization-
aboratory use with abciximab based on the decision after
iagnostic angiography to proceed to PCI. The upstream
se of the cheaper small molecules was found to be cost
ffective in comparison with the use of the more expensive
bciximab when the patients were at moderate or high risk
s assessed by the Thrombolysis In Myocardial Infarction
TIMI) risk score. Based on the clinical trial data used
y the investigators, when the probability of PCI increased
o 90%, the use of abciximab was more cost effective.
ith close to universal use of the more expensive abcix-
mab, the cost effectiveness of the small molecules would
nly be lost if the actual clinical outcome of abciximab is
uperior, as indicated by the results of the TARGET trial,
hich was used for the cost-effectiveness analysis. However,
he TARGET trial did not use an upstream approach. If the
esults of the more relevant EVEREST study are correct,
hen the advantage of the small molecules, when initiated
pstream, would be maintained in all moderate-risk and
igh-risk patients. The data from the EVEREST trial are
lso consistent with the low event rate seen in the invasive
rm of TACTICS-TIMI 18 (10).
The two studies highlighted above as well as the other
ata available from clinical trials provide us with better
vidence-based management of patients with acute coronary
yndrome, whereas certain lingering questions remain:
) The benefit of potent anti-platelet agents is likely to
occur in patients with plaque rupture and superimposed
platelet aggregation, and therefore identification of
high-risk patients is crucial. Use of GP IIb/IIIa agents
in patients with chest pain but without platelet activa-
tion (for example because of progression of stable
plaque) would not be expected to benefit from GP
IIb/IIIa blockers, and may even be harmed. The use of
biomarkers such as troponin I (19) (evidence of possible
distal embolization) and s-cd40L (evidence of platelet
activation) as well as the TIMI risk score, B-type
natriuretic peptide, and ST-segment depressions, help
in identifying the high-risk patient likely to benefit from
upstream use.
) The increasing use of clopidogrel, particularly with
higher-dose loading, has generated data in patients with
1lower risk (such as elective PCI patients) showing that
such therapy may be sufficient (20). Data in high-risk
patients, however, still show incremental platelet inhi-
bition with the GP IIb/IIIa antagonists (21).
) The use of in-laboratory abciximab is still appropriate in
patients who have not received a GP IIb/IIIa upstream,
and remains the GP IIb/IIIa of choice in STEMI
patients treated with primary PCI (should be started
prior to arrival in the catheterization laboratory if
possible).
) The use of selective/bailout GP IIb/IIIa blockers in the
setting of direct thrombin inhibitors seems promising
(22), but requires further validation in larger prospective
trials in high-risk patients.
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